Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience. The Company's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease dementia. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. It is conducting two randomized placebo-controlled Phase III clinical trials of oral simufilam in patients with Alzheimer’s disease dementia. SavaDx, its lead investigational diagnostic product candidate, is a way to detect the presence of Alzheimer’s disease from a small sample of blood. SavaDx is a research-use only, non-safety related exploratory biomarker.

• Revenue in USD (TTM)0.00
• Net income in USD-17.66m
• Incorporated1998
• Employees29.00

• Location
  Cassava Sciences6801 N CAPITAL OF TEXAS HIGHWAYBUILDING 1; SUITE 300AUSTIN 78731United StatesUSA
• Phone+1 (512) 501-2444
• Fax+1 (512) 614-0414
• Websitehttps://www.cassavasciences.com/